Fracture risk down with adherence to bisphosphonates

Fracture risk down with adherence to bisphosphonates
For patients with an osteoporotic fracture, adherence to bisphosphonate treatment is associated with reduced fracture risk; and for veterans with rheumatoid arthritis, non-adherence to bisphosphonate treatment is over 50 percent, according to two studies published in the December issue of Arthritis Care & Research.

(HealthDay)—For patients with an osteoporotic fracture, adherence to bisphosphonate treatment is associated with reduced fracture risk; and for veterans with rheumatoid arthritis, non-adherence to bisphosphonate treatment is over 50 percent, according to two studies published in the December issue of Arthritis Care & Research.

In the first study, Jeffrey R. Curtis, M.D., M.P.H., from the University of Alabama at Birmingham, and colleagues used data from Medicare 2006 to 2009 to compare fracture risk associated with medication adherence nine months after an osteoporotic fracture in 2,507 patients initiating oral bisphosphonates; 2,420 patients initiating selective serotonin reuptake inhibitors (SSRIs); and 2,178 patients initiating an angiotensin-converting enzyme (ACE) inhibitor or calcium-channel blocker (CCB). The researchers found that high adherence to bisphosphonates correlated with lower fracture risk at the hip and major fracture sites, while high adherence to SSRIs correlated with a non-significantly increased fracture risk and high adherence to ACE inhibitors/CCBs had no effect on .

In the second study, J. Steuart Richards, M.B.B.S., from the Veterans Affairs Medical Center in Washington, D.C., and colleagues examined adherence to bisphosphonate treatment in 1,382 U.S. veterans with , where 573 (41.5 percent) were prescribed bisphosphonates. The researchers found that 52.7 percent were non-adherent, and after multivariable adjustment, non-adherence to treatment correlated with a longer duration of rheumatoid arthritis disease and bisphosphonate therapy lasting >32 months. Whites were significantly less likely to have a low medication possession ratio.

"In summary, in a cohort of veterans with rheumatoid arthritis, oral bisphosphonate is subpar, and our findings provide baseline data to permit a targeted approach for improvement in fracture prevention interventions," Richards and colleagues conclude.

The Curtis study was supported by Amgen. One author is an employee of Procter & Gamble and Amgen.

More information: Abstract - Curtis
Full Text (subscription or payment may be required)
Abstract - Richards
Full Text (subscription or payment may be required)

Related Stories

Meds adherence self-report valid in type 2 diabetes

date Dec 20, 2012

(HealthDay)—Self-reported measures of medication adherence in adults with type 2 diabetes are valid, although some self-reports are moderated by depression, according to a study published online Nov. 30 ...

Recommended for you

New test could predict arthritis drug failure in patients

date Jul 03, 2015

A study of 311 patients by The University of Manchester has found that it may be possible to predict early which rheumatoid arthritis (RA) patients will fail to respond to the biologic drugs given to treat them. These findings ...

About 8 percent of SLE patients have pulmonary HTN

date Jun 23, 2015

(HealthDay)—About 8 percent of patients with systemic lupus erythematosus (SLE) have pulmonary hypertension (PH), and serum uric acid (UA) has reasonable accuracy for predicting PH, according to a study ...

Early age of menopause linked to seropositivity in RA

date Jun 17, 2015

(HealthDay)—In women with early rheumatoid arthritis (RA), early age at menopause is associated with seropositivity, according to a study published in the May issue of Arthritis Care & Research.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.